Studies have already shown that phytocannabinoids like cannabidiol have promising results in opioid withdrawal symptoms and heroin-seeking behavior.
These findings reopen the discussion about the ability of other phytocannabinoids, whose mechanism of action was unknown, to bind directly to cannabinoid receptors as Δ 9-THC does.
The research is focused on developing a drug that enables patients to benefit from the medicinal benefits of THC without experiencing its inherit psychoactive properties.
The natural healing properties of CBD are being jeopardized by the advent of man-made synthetic CBDs.
The regulations set forth by California's Bureau of Cannabis Control (BCC) state that beginning July 1, a licensed retailer may only sell cannabis goods that have met all state-mandated testing requirements.
This first-of-its-kind process enables the company to produce cGMP-compliant, pure THC molecules to be used as the active pharmaceutical ingredient in products currently undergoing research for multiple conditions.
Though almost half of oncologists surveyed recommend medical marijuana clinically, less than a third feel equipped with enough knowledge to make such recommendations.